Earnings Call Summary | G1 Therapeutics(GTHX.US) Q4 2023 Earnings Conference
Earnings Call Summary | G1 Therapeutics(GTHX.US) Q4 2023 Earnings Conference
The following is a summary of the G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript:
以下是G1 Therapeutics, Inc.（GTHX）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
G1 Therapeutics reported Q4 2023 revenue of $14.9 million, up 45% YoY.
Sales from COSELA were $13.9 million and license revenue contributed $1 million.
Total revenue for FY 2023 was $82.5 million, showing a significant growth from $51.3 million in FY 2022.
Operating expenses decreased by 35%, and the company ended the quarter with cash, cash equivalents, and marketable securities of $82.2 million.
Net COSELA revenue is projected to be between $60 and $70 million for 2024, with a year-end cash balance expected to range from $50 to $60 million.
G1 Therapeutics報告稱，2023年第四季度收入爲1,490萬美元，同比增長45％。
COSELA的銷售額爲1,390萬美元，許可收入貢獻了100萬美元。
2023財年的總收入爲8,250萬美元，較2022財年的5,130萬美元大幅增長。
運營支出下降了35％，公司在本季度末的現金、現金等價物和有價證券爲8,220萬美元。
預計2024年，COSELA的淨收入將在6000萬至7000萬美元之間，年終現金餘額預計在5000萬至6000萬美元之間。
Business Progress:
業務進展：
G1 is expecting results from ongoing Phase 3 PRESERVE 2 trial of trilaciclib in metastatic settings by the third quarter.
The year ahead sees promise with the use of ADCs in second line and TNBC treatment settings.
G1's commercial team is focusing on driving COSELA penetration, aiming to reduce chemotherapy-related myelosuppressive side effects.
The sales performance surpassed expectations, with 19% overall vial volume growth compared to Q3 2023.
The focus remains on continued volume growth and sales, with the company adding 2 new top 100 customers in Q4.
G1 continues advancing its clinical trials with promising initial results from the trilaciclib plus TROP2 ADC sacituzumab govitecan Phase 2 trial.
The company is keen on extending its cash runway into 2025, despite various implementation costs, and remains proactive in identifying potential efficiency improvements.
G1預計，正在進行的用於轉移性環境的曲拉西利布的3期PRESERVE 2試驗將在第三季度之前取得結果。
未來一年，在二線和TNBC治療環境中使用ADCs前景看好。
G1的商業團隊專注於推動COSELA的普及，旨在減少與化療相關的骨髓抑制副作用。
銷售業績超出預期，與2023年第三季度相比，小瓶總銷量增長了19％。
重點仍然是持續的銷量增長和銷售，該公司在第四季度增加了2個新的前100名客戶。
G1 繼續推進其臨床試驗，曲拉西利布加 TROP2 ADC sacituzumab govitecan 2 期試驗的初步結果令人鼓舞。
儘管實施成本各不相同，但該公司仍熱衷於將其現金流延長至2025年，並且仍在積極尋找潛在的效率改進措施。
More details: G1 Therapeutics IR
更多詳情： G1 Therapeutics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。